Skip to content
Adrienne Monson – Lifestyle
Author:
Virax BioLabs Group Limited
Virax Biolabs’ CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement
July 16, 2026
Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
July 10, 2026
Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
July 9, 2026
Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics
July 9, 2026
Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation
June 24, 2026
Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
May 26, 2026
Virax Biolabs’ CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders
April 14, 2026
Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation
March 31, 2026